Depression and Quality of Life in Parkinson's Disease

Depression is one of the most prevalent non-motor manifestations of Parkinson’s disease (PD), affecting up to 60 per cent of patients at various stages of the condition. Its aetiology reflects a complex interplay between neurobiological changes—particularly dopaminergic degeneration in mesolimbic and mesocortical pathways—and psychological responses to a progressive movement disorder. Depressive symptoms in PD often include anhedonia, apathy and reduced motivation, which can precede motor features by several years. These affective disturbances contribute substantially to diminished health-related quality of life, compounding disability, impairing social participation and increasing caregiver burden. Despite the known impact on physical, emotional and psychosocial domains, depression in PD remains under-recognised and under-treated, in part because the overlap between motor and mood symptoms can obscure accurate diagnosis. Effective management demands a holistic approach encompassing optimised dopaminergic therapy, judicious use of antidepressants selected for safety in PD, and integration of non-pharmacological strategies such as cognitive behavioural therapy and structured exercise. Early identification and targeted interventions are critical to preserve overall well-being and to mitigate the cumulative effects of mood disturbance on daily functioning.

Research from Nature Portfolio

Recent studies have elucidated how distinct dopaminergic therapies differentially influence dimensions of depression in PD. Large longitudinal data reveal that dopamine agonists preferentially ameliorate motivational deficits—such as diminished drive and initiation—whereas monoamine oxidase-B inhibitors yield broader improvements spanning both motivational and core mood symptoms. Notably, the efficacy of these agents varies with the extent of striatal dopamine depletion, highlighting the need to individualise pharmacological regimens according to disease stage and neurodegenerative burden.

Depression and Quality of Life in Parkinson's Disease publication trend

The graph below shows the total number of articles in depression and quality of life in parkinson's disease across all publications each year (not limited to Nature Index journals).

Technical terms

Non-motor symptom: A feature of Parkinson’s disease not related to movement, such as depression or cognitive dysfunction.

Motivational symptom: A deficit in drive or goal-directed behaviour often linked to dopaminergic loss in reward circuits.

Monoamine oxidase-B (MAO-B) inhibitor: A drug that prevents the breakdown of dopamine in the brain, used to augment endogenous dopamine levels.

Cognitive behavioural therapy (CBT): A structured psychological treatment that addresses maladaptive thoughts and behaviours to improve mood.

Quality of life: A multidimensional measure of an individual’s overall well-being, encompassing physical health, psychological state and social relationships.

References

1. Depressive symptoms in Parkinson’s disease are insufficiently but more often treated than in other chronic conditions. npj Parkinson's Disease (2023).
2. Dissociable effects of dopaminergic medications on depression symptom dimensions in Parkinson disease. Nature Mental Health (2024).
3. German Society of Neurology guidelines for the diagnosis and treatment of cognitive impairment and affective disorders in people with Parkinson’s disease: new spotlights on diagnostic procedures and non-pharmacological interventions. Journal of Neurology (2024).
4. An Investigation on the Clinical Features and Neurochemical Changes in Parkinson's Disease With Depression. Frontiers in Psychiatry (2019).